Goldfinch Bio has appointed Kyle Kuvalanka to serve as chief financial and chief operating officer. His experience includes positions at Syros Pharmaceuticals, Blueprint Medicines (NASDAQ: [[ticker:BPMC]]), and Takeda Pharmaceutical (NYSE: [[ticker:TAK]]).
In other moves, Cambridge, MA-based Goldfinch promoted Lori Rudolph-Owen to chief development officer. She joined the company in 2018 as senior vice president of R&D strategy and operations. Her previous experience include positions at Tesaro, Pfizer (NYSE: [[ticker:PFE]]), AMAG Pharmaceuticals (NASDAQ: [[ticker:AMAG]]), and MGI Pharma. Goldfinch is developing treatments for kidney diseases. The biotech is preparing to advance lead candidate, GFB-887, to Phase 2 tests as a potential treatment for focal segmental glomerulosclerosis and diabetic neuropathy.
